

## References

### I-227

1. Cree B, Bennett J, Kim H, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-Momentum): a double-blind, randomized placebo-controlled phase 2/3 trial. *Lancet*. 2019;394(1029):1352-1363.
2. Agius M, Klodowska-Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. *Mult Scler*. 2019;25(2):235-245.
3. Clinical Pharmacology™ 2020. Tampa FL: Gold Standard, Inc. Inebilizumab.
4. Hayes, Inc. Hayes Emerging Technology Report. Uplizna (Inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder. Lansdale, PA: Hayes, Inc.; June, 2020.
5. Uplizna (inebilizumab-cdon), injection, for intravenous use. [package insert]. Viela Bio, Inc. Gaithersburg, MD. 06/2020.